Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Foghorn Therapeutics Inc. FHTX

Foghorn Therapeutics Inc. is a clinical-stage biotechnology company engaged in developing medicines that modulate gene expression through selectively targeting the chromatin regulatory system for therapeutic intervention in oncology. Its Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact... see more

Recent & Breaking News (NDAQ:FHTX)

Foghorn Therapeutics to Participate in the Bank of America 2022 Precision Oncology Conference

GlobeNewswire September 27, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Foghorn Therapeutics Inc. - FHTX

Newsfile September 17, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX

Newsfile September 1, 2022

Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences

GlobeNewswire September 1, 2022

Foghorn Therapeutics Announces Change to Board of Directors

GlobeNewswire August 31, 2022

Foghorn Therapeutics Provides Further Update on FHD-286 Phase I Study in Relapsed/Refractory AML/MDS

GlobeNewswire August 23, 2022

Foghorn Therapeutics Appoints Lynne Parshall to its Board of Directors

GlobeNewswire August 17, 2022

Foghorn Therapeutics Provides Second Quarter 2022 Financial and Corporate Update

GlobeNewswire August 9, 2022

Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences

GlobeNewswire August 1, 2022

Foghorn Therapeutics Announces Upcoming Investor Conference Participation

GlobeNewswire May 31, 2022

Foghorn Therapeutics Provides Update on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML and MDS

GlobeNewswire May 19, 2022

SHAREHOLDER ALERT: Weiss Law Reminds LHCG, NLSN, GDNSF, and MSP Shareholders About Its Ongoing Investigations

PR Newswire May 11, 2022

Datto Leaders Named to CRN's 2022 Women of the Channel and Power 100 Lists

Business Wire May 11, 2022

Datto Announces First Quarter 2022 Financial Results

Business Wire May 9, 2022

Foghorn Therapeutics Provides First Quarter 2022 Corporate Update

GlobeNewswire May 9, 2022

SHAREHOLDER ALERT: Weiss Law Reminds LHCG, NLSN, GDNSF, and MSP Shareholders About Its Ongoing Investigations

PR Newswire May 4, 2022

SHAREHOLDER ALERT: Weiss Law Reminds LHCG, NLSN, GDNSF, and MSP Shareholders About Its Ongoing Investigations

PR Newswire April 26, 2022

 Datto Launches Two Continuity Solutions that Provide the Last Line of Defense for MSPs Against Cyberattacks

Business Wire April 26, 2022

SHAREHOLDER ALERT: Weiss Law Reminds MSP, SAIL, SAVE, and EXTN Shareholders About Its Ongoing Investigations

PR Newswire April 19, 2022

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Datto Holding Corp. Buyout

Newsfile April 18, 2022